What is the recommended approach to diagnose and treat restless leg syndrome (RLS), including iron studies, first‑line dopamine agonist therapy, alternative medications, and non‑pharmacologic measures?

Restless Legs Syndrome: Diagnosis and Treatment

Diagnostic Approach

Restless Legs Syndrome is a clinical diagnosis based on four essential criteria: an urge to move the legs (usually with uncomfortable sensations), worsening with rest or inactivity, relief with movement, and evening/nighttime predominance. 1

Essential Iron Studies

• Check morning fasting serum ferritin and transferrin saturation in all patients with clinically significant RLS, ideally after withholding iron supplements for at least 24 hours. 1
• Obtain a complete blood count simultaneously to screen for anemia. 1
• RLS-specific iron thresholds differ from general population guidelines:
  • Adults: Supplement when ferritin ≤75 ng/mL or transferrin saturation <20%. 1
  • Children: Supplement when ferritin <50 ng/mL. 1

Identify Exacerbating Factors

• Screen for medications that worsen RLS: antihistamines, serotonergic antidepressants (SSRIs, tricyclics), antipsychotics (dopamine antagonists like olanzapine, lurasidone), lithium, and bupropion. 1, 2
• Assess for untreated obstructive sleep apnea, which must be addressed as part of RLS management. 1
• Evaluate alcohol, caffeine, and nicotine use—particularly evening consumption. 1

First-Line Treatment Algorithm

Step 1: Iron Repletion (When Indicated)

Iron therapy is the foundation of RLS management when ferritin ≤75 ng/mL or transferrin saturation <20%. 1

• Oral iron: Ferrous sulfate 325 mg once daily or every other day (conditional recommendation, moderate certainty). 1
• IV iron (preferred for rapid correction): Ferric carboxymaltose 750–1000 mg in one or two infusions (strong recommendation, moderate certainty). 1
  • Consider IV iron even when ferritin is 75–100 ng/mL if oral therapy fails or is not tolerated. 1
  • IV iron can be effective even when prior oral supplementation has failed. 1

Step 2: First-Line Pharmacologic Therapy

Alpha-2-delta ligands are now strongly recommended as first-line agents for RLS, replacing dopamine agonists due to the high risk of augmentation (7–10% annually). 3, 1

• Gabapentin: Start 300 mg three times daily; increase by 300 mg/day every 3–7 days; target maintenance 1800–2400 mg/day divided TID; maximum 3600 mg/day (strong recommendation, moderate certainty). 1
• Gabapentin enacarbil: Prodrug with improved bioavailability (strong recommendation, moderate certainty). 1
• Pregabalin: Start 50 mg TID or 75 mg BID; after 3–7 days increase to 300 mg/day; may raise by 150 mg every 3–7 days; maximum 600 mg/day (strong recommendation, moderate certainty). 1
  • Pregabalin allows twice-daily dosing and may have superior bioavailability compared to regular gabapentin. 1

Common Side Effects of Alpha-2-Delta Ligands

• Somnolence and dizziness are typically transient and mild. 1
• Monitor for fall risk, particularly in elderly patients. 1
• Avoid in patients with untreated obstructive sleep apnea or COPD due to respiratory depression risk. 1

Dopamine Agonists: Use with Extreme Caution

The 2025 American Academy of Sleep Medicine guidelines represent a major shift: dopamine agonists are now recommended AGAINST for standard use due to augmentation risk. 3, 1

Augmentation Phenomenon

• Augmentation is a paradoxical worsening of RLS symptoms characterized by:
  • Earlier daily onset (afternoon instead of evening). 1
  • Increased symptom intensity. 1
  • Spread to arms, trunk, or previously unaffected body regions. 1
• Annual incidence: 7–10% with dopamine agonists. 1

Specific Recommendations

• Pramipexole: Conditional recommendation against standard use (moderate certainty). 3
• Ropinirole: Conditional recommendation against standard use (moderate certainty). 3
• Rotigotine (transdermal): Conditional recommendation against standard use (low certainty). 3
• Levodopa: Conditional recommendation against standard use (very low certainty). 3
• Cabergoline: Strong recommendation AGAINST use (moderate certainty) due to cardiac valvular fibrosis risk. 3

These agents may be considered ONLY for short-term use in patients who prioritize immediate symptom relief over long-term adverse effects—this is explicitly NOT the standard approach. 3, 1

Managing Dopaminergic Augmentation

If a patient is already on a dopamine agonist and develops augmentation, DO NOT increase the dose—this worsens the problem. 1

Transition Strategy

1. Add an alpha-2-delta ligand (e.g., gabapentin 300 mg TID, titrated to 1800–2400 mg/day) or an opioid before tapering the dopamine agonist. 1
2. Once symptom control is achieved, taper the dopamine agonist very slowly (reduce by 0.125–0.25 mg pramipexole-equivalent every 1–2 weeks). 1
3. Anticipate rebound RLS and insomnia; short-acting opioids or clonidine may serve as temporary bridge therapy. 1
4. For severe augmentation, bypass alpha-2-delta ligands and transition directly to an opioid. 1

Refractory RLS: Second-Line Options

Refractory RLS is defined as persistent symptoms despite optimized iron status (ferritin >75 ng/mL, transferrin saturation >20%), therapeutic trials of alpha-2-delta ligands, and elimination of aggravating factors. 1

Opioid Therapy

• Extended-release oxycodone 5–10 mg at bedtime is conditionally recommended for moderate to severe refractory RLS (moderate certainty). 1
• Methadone 5–10 mg daily provides 24-hour symptom coverage with low augmentation risk and stable dosing. 1
• Buprenorphine (transdermal or sublingual) has a similar safety profile. 1
• Long-term studies show only modest dose escalation over 2–10 years and relatively low abuse risk when patients are appropriately screened. 1

Safety Considerations Before Opioid Initiation

• Screen for opioid-use-disorder risk using validated assessment tools. 1
• Evaluate for untreated obstructive sleep apnea—opioids increase respiratory depression and central sleep apnea risk. 1
• Monitor respiratory status closely, especially during the first weeks. 1
• Counsel about constipation (most common adverse effect) and prescribe prophylactic stool softeners. 1

Non-Pharmacologic Alternative

• Bilateral high-frequency peroneal nerve stimulation is conditionally recommended (moderate certainty) as a non-invasive option for patients who refuse or cannot tolerate opioids. 1

Medications to Avoid

The following agents have conditional or strong recommendations AGAINST use in RLS: 3, 1

• Bupropion (conditional, moderate certainty). 3
• Carbamazepine (conditional, low certainty). 3
• Clonazepam (conditional, very low certainty)—provides sedation only; does not reduce periodic limb movements. 3, 1
• Valproic acid (conditional, low certainty)—hepatotoxicity and teratogenicity risks. 3
• Valerian (conditional, very low certainty). 3
• Tizanidine—no evidence supporting its use in RLS. 1

Special Populations

End-Stage Renal Disease (ESRD)

• Gabapentin: Start 100 mg post-dialysis or at bedtime; maximum 200–300 mg daily (conditional, very low certainty). 3, 1
• IV iron sucrose: Indicated when ferritin <200 ng/mL and transferrin saturation <20% (conditional, moderate certainty). 3, 1
• Vitamin C supplementation may improve iron utilization (conditional, low certainty). 3, 1
• Avoid pregabalin in ESRD—markedly increases hazard of altered mental status and falls. 1

Pediatric RLS

• Ferrous sulfate is conditionally recommended when ferritin <50 ng/mL (very low certainty). 3, 1
• Monitor for constipation as a common side effect. 1

Pregnancy

• Iron supplementation is particularly important given pregnancy-specific RLS prevalence. 1
• Safety profile favors oral iron formulations throughout gestation. 1
• Consider medication safety profiles carefully—alpha-2-delta ligands and dopamine agonists have varying pregnancy categories. 1

Non-Pharmacologic Measures

• Eliminate or reduce alcohol, caffeine, and nicotine—particularly within 3 hours of bedtime. 1
• Avoid heavy meals close to bedtime. 1
• Optimize sleep environment: dark, quiet, comfortable temperature. 1
• Regular morning/afternoon exercise; avoid vigorous exercise close to bedtime. 1
• Increase daytime bright light exposure; avoid nighttime bright light. 1

Monitoring and Follow-Up

• Reassess RLS severity at 4–6 weeks after treatment initiation. 1
• Repeat iron studies every 6–12 months—brain iron deficiency may persist despite clinical improvement. 1
• Monitor for side effects of alpha-2-delta ligands (dizziness, somnolence). 1
• Evaluate both nighttime symptom relief and daytime functional outcomes (alertness, mood, quality of life). 1
• For patients on opioids, assess for respiratory depression, constipation, and sedation. 1

Critical Pitfalls to Avoid

• Do not assume normal serum iron studies exclude iron deficiency in RLS—brain iron deficiency in specific regions drives dopamine dysfunction even with normal peripheral markers. 1, 4
• Do not increase dopamine-agonist doses when symptoms worsen—this likely reflects augmentation and will worsen the problem. 1
• Do not use clonazepam as monotherapy—it improves subjective sleep quality but does not reduce objective disease markers. 1, 2
• Do not label RLS as refractory without first optimizing iron status—patients with ferritin 75–100 ng/mL may still benefit from IV iron. 1
• Do not withhold opioids from appropriately screened patients with severe refractory RLS—evidence supports their use with low long-term abuse risk. 1
• Do not combine multiple sedating agents (opioids + alpha-2-delta ligands + benzodiazepines) without first treating obstructive sleep apnea. 1